Endologix Reports Positive Clinical Data from Ovation® LIFE (Least Invasive Fast-Track EVAR) Study

IRVINE, Calif., Sept. 20, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Ovation^® LIFE (Least Invasive Fast-Track EVAR) study. Zvonimir Krajcer, MD, FACC, Co-Director, Peripheral Vascular Disease Service at Texas Heart Institute in Houston, TX, and one of the co-national principal investigators in the LIFE study, presented the results in a late breaking session at Vascular InterVentional Advances (VIVA), which is being held September 18-22 in Las Vegas, NV.

The LIFE study, which prospectively enrolled 250 patients at 34 centers in the United States, is designed to evaluate the Ovation^® Abdominal Stent Graft platform when used in the treatment of patients with abdominal aortic aneurysms ("AAA").  The LIFE study is the first of its kind using a Fast-Track EVAR protocol, which includes bi-lateral percutaneous access enabled by Ovation’s ultra-low profile (14F) design, avoidance of general anesthesia and intensive care unit (“ICU”) admission post procedure, and next-day discharge.

Data from the LIFE study demonstrated that Ovation met the study primary endpoint for major adverse events at 30 days. Key highlights of the presentation, with outcomes covering one-month follow-up, include:

• Low major adverse event (MAE) rate of 0.4%
• No ruptures, conversion, or secondary interventions
• 99% and 100% freedom from type I and type III endoleak
• Fast-Track completed in 216 (87%) patients, with positive results compared to non-Fast-Track patients:
  • Procedure time of 84 minutes vs. 110 minutes
  • General anesthesia use 0% vs. 18%
  • ICU stay 0% vs. 32%
  • Mean hospital stay 1.2 vs. 1.9 days

A cost utility analysis compared Fast-Track EVAR to an EVAR control group of 8,306 patients identified from a contemporary inpatient discharge database. Completion of the Fast-Track protocol was associated with over $21,000 in perioperative cost savings per patient relative to standard EVAR, largely driven by differences in hospital costs.  Additionally, the 30-day EVAR hospital readmission rate in the LIFE study was 1.6%, compared to 8% from the American College of Surgeons National Surgical Quality Improvement Program.

Dr. Krajcer commented, “The LIFE study provides the first clinical evidence that a Fast-Track protocol for EVAR offers a safe and cost-effective option for eligible AAA patients. Patients in the Fast-Track treatment group did not require ICU admission and benefitted from shorter procedure times and hospital stays. This has the potential to drive significant perioperative cost-savings compared to standard EVAR for hospitals, while also improving clinical outcomes. The LIFE study provides compelling evidence to support the adoption of Ovation and the implementation of the Fast-Track protocol in EVAR centers.”

John McDermott, Chairman and Chief Executive Officer of Endologix, said, “We are extremely pleased with the positive results from the LIFE study.  The outstanding clinical outcomes combined with the significant cost savings provides evidence that Ovation used in conjunction with the Fast-Track protocol is better for patients, hospitals and payors.  We look forward to building awareness of these results and working with clinicians and hospitals to adopt Ovation and the Fast-Track protocol for their AAA patients.”

About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

Forward-Looking Statements
This communication includes statements that may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the potential adoption of a Fast-Track protocol by clinicians and hospitals, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including unanticipated clinical outcomes and competitive pressures.  Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Endologix undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix's Annual Report on Form 10-K for the year ended December 31, 2015, and Endologix's subsequent filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com 

INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020